Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous ceftriaxone 2 g in inpatients with infection
ACTRN12624000692538Phase 4Recruiting
- Sponsor
- Fiona Stanley Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ceftriaxone in Infection (2 arms), sponsored by Fiona Stanley Hospital. Primary endpoint: Safety and tolerability of subcutaneous ceftriaxone 2 g. Started Jun 2024; status: recruiting.
02
Drugs
ceftriaxone
03
Conditions
Infection
Beyond the preview
Go deeper on ACTRN12624000692538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000692538.